SynthesisCardiology journal2025
Eustachian valve endocarditis in the context of right atrial embryonic remnants: A systematic review and meta-analysis.
Synthesis in Cardiology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEustachian valve endocarditis (EVE) is a rare right-sided infective endocarditis (RSIE) manifestation. This condition has scattered and limited clinical characteristics that require collection and systematization. This meta-analysis evaluates the predisposing factors, pathogens, and associated risk profiles in EVE cases.
methodsThe meta-analysis included 68 cases of EVE from 57 reports published between 1986 and 2024 from PubMed, Embase, Scopus, Cochrane, and Web of Science. Data on demographics, clinical characteristics, risk factors, and microbiological findings were extracted and analyzed using descriptive and univariate statistical methods. Pooled prevalence rates from observational studies were calculated using a fixed effects model.
resultsThe pooled prevalence of EVE in RSIE among the analyzed cases was 2.54%. Single-valve infections accounted for 70.6% of cases, with the Eustachian valve as the sole affected structure. The most common pathogen was Staphylococcus aureus (60%), predominantly affecting younger intravenous drug users (IVDU) with an odds ratio [OR (odds ratio) = 6.27; 95% CI (confidence interval): 1.62-24.31] in univariate logistic regression analysis. Other predisposing factors, including central venous catheters (CVCs) and cardiac implantable electronic devices (CIED), were not significantly associated with Staphylococcus aureus or other bacterial non-Staphylococcus aureus or fungal infections.
conclusionsEustachian valve endocarditis is relatively rare and primarily associated with IVDU and younger age, whereas CVCs and CIEDs are insignificant predictors. Identifying embryonic remnants like the Eustachian valve or Chiari network using echocardiography may facilitate early diagnosis in at-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.